MA38153A1 - Polypeptides stabilisés de facteur de croissance de type insuline - Google Patents

Polypeptides stabilisés de facteur de croissance de type insuline

Info

Publication number
MA38153A1
MA38153A1 MA38153A MA38153A MA38153A1 MA 38153 A1 MA38153 A1 MA 38153A1 MA 38153 A MA38153 A MA 38153A MA 38153 A MA38153 A MA 38153A MA 38153 A1 MA38153 A1 MA 38153A1
Authority
MA
Morocco
Prior art keywords
growth factor
factor polypeptides
stabilized insulin
polypeptides
igf
Prior art date
Application number
MA38153A
Other languages
Arabic (ar)
English (en)
Other versions
MA38153B1 (fr
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38153A1 publication Critical patent/MA38153A1/fr
Publication of MA38153B1 publication Critical patent/MA38153B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne le domaine des modifications d'igf-1. En particulier, l'invention concerne des polypeptides igf modifiés et des polypeptides précurseurs d'igf-1 modifiés où le clivage du peptide e est empêché. L'invention concerne également l'utilisation de tels polypeptides pour le traitement de maladies et de troubles musculaires.
MA38153A 2012-12-18 2013-12-16 Polypeptides stabilisés de facteur de croissance de type insuline MA38153B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (fr) 2012-12-18 2013-12-16 Polypeptides stabilisés de facteur de croissance de type insuline

Publications (2)

Publication Number Publication Date
MA38153A1 true MA38153A1 (fr) 2016-06-30
MA38153B1 MA38153B1 (fr) 2018-06-29

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38153A MA38153B1 (fr) 2012-12-18 2013-12-16 Polypeptides stabilisés de facteur de croissance de type insuline

Country Status (36)

Country Link
US (1) US10167329B2 (fr)
EP (2) EP3626735A1 (fr)
JP (1) JP6499080B2 (fr)
KR (1) KR102182523B1 (fr)
CN (1) CN105121462B (fr)
AP (1) AP2015008440A0 (fr)
AU (1) AU2013365796B2 (fr)
BR (1) BR112015013708B1 (fr)
CA (1) CA2894976C (fr)
CL (1) CL2015001708A1 (fr)
CR (2) CR20200079A (fr)
CU (1) CU24308B1 (fr)
CY (1) CY1122309T1 (fr)
DK (1) DK2935320T3 (fr)
EA (1) EA034356B1 (fr)
EC (1) ECSP15031046A (fr)
ES (1) ES2756330T3 (fr)
GT (1) GT201500168A (fr)
HR (1) HRP20191965T1 (fr)
HU (1) HUE047386T2 (fr)
IL (1) IL239387A0 (fr)
LT (1) LT2935320T (fr)
MA (1) MA38153B1 (fr)
MX (1) MX363021B (fr)
MY (1) MY174820A (fr)
NZ (1) NZ708091A (fr)
PE (2) PE20200894A1 (fr)
PH (1) PH12015501271A1 (fr)
PL (1) PL2935320T3 (fr)
PT (1) PT2935320T (fr)
RS (1) RS59545B1 (fr)
SA (1) SA515360603B1 (fr)
SG (1) SG11201503782PA (fr)
SI (1) SI2935320T1 (fr)
TN (1) TN2015000182A1 (fr)
WO (1) WO2014097116A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271265A1 (en) * 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (fr) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Composés et procédés pour l'immobilisation des inhibiteurs de myostatine sur la matrice extracellulaire par la transglutaminase
EP4606428A3 (fr) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Polypeptides associés à l'héparine et leurs utilisations
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (fr) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Polypeptides régénérateurs et leurs utilisations
WO2025106529A2 (fr) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions destinées au ciblage de cellules musculaires et leurs utilisations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
WO2002085923A2 (fr) 2001-04-19 2002-10-31 The Scripps Research Institute Incorporation in vivo d'acides amines non naturels
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
JP4988599B2 (ja) 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
PL3075858T3 (pl) 2007-12-21 2020-07-13 Novartis Ag Ssaczy wektor ekspresyjny
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
WO2011011073A1 (fr) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Igf-1 pégylé spécifique de site ou lipidé spécifique de site et analogues de l’igf-1
WO2011011071A2 (fr) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues au facteur-1 de croissance analogue à l'insuline (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
AP2015008440A0 (en) 2015-05-31
MA38153B1 (fr) 2018-06-29
CU20150064A7 (es) 2016-02-29
US20150329614A1 (en) 2015-11-19
NZ708091A (en) 2018-03-23
KR102182523B1 (ko) 2020-11-25
GT201500168A (es) 2016-01-21
CU24308B1 (es) 2018-01-10
PT2935320T (pt) 2019-11-15
CR20150324A (es) 2015-08-10
HUE047386T2 (hu) 2020-04-28
EA201591165A1 (ru) 2015-11-30
SG11201503782PA (en) 2015-06-29
ES2756330T3 (es) 2020-04-27
EP2935320B1 (fr) 2019-08-21
JP2016501025A (ja) 2016-01-18
AU2013365796B2 (en) 2017-03-30
JP6499080B2 (ja) 2019-04-10
ECSP15031046A (es) 2019-03-29
MY174820A (en) 2020-05-17
AU2013365796A1 (en) 2015-05-28
PL2935320T3 (pl) 2020-03-31
EP3626735A1 (fr) 2020-03-25
IL239387A0 (en) 2015-07-30
CN105121462B (zh) 2019-08-02
CY1122309T1 (el) 2021-01-27
CL2015001708A1 (es) 2015-08-28
BR112015013708B1 (pt) 2022-10-18
US10167329B2 (en) 2019-01-01
LT2935320T (lt) 2019-11-11
CR20200079A (es) 2020-03-21
EA034356B1 (ru) 2020-01-30
MX2015007932A (es) 2015-10-05
RS59545B1 (sr) 2019-12-31
HK1212712A1 (en) 2016-06-17
TN2015000182A1 (en) 2016-10-03
CA2894976A1 (fr) 2014-06-26
HRP20191965T1 (hr) 2020-01-24
CN105121462A (zh) 2015-12-02
PE20151612A1 (es) 2015-11-19
SA515360603B1 (ar) 2020-07-26
MX363021B (es) 2019-03-05
PH12015501271B1 (en) 2015-08-24
BR112015013708A2 (pt) 2017-11-14
DK2935320T3 (da) 2019-11-18
SI2935320T1 (sl) 2019-12-31
EP2935320A1 (fr) 2015-10-28
PH12015501271A1 (en) 2015-08-24
KR20150095879A (ko) 2015-08-21
CA2894976C (fr) 2022-10-04
PE20200894A1 (es) 2020-09-08
WO2014097116A1 (fr) 2014-06-26

Similar Documents

Publication Publication Date Title
MA38153A1 (fr) Polypeptides stabilisés de facteur de croissance de type insuline
IL266705B (en) Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming
EA201690314A1 (ru) Анти-garp-белок и его применения
SG11201600734YA (en) Stabilization of fc-containing polypeptides
IL243209B (en) Cyclic peptides as protein targeting agents
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2016001093A (es) Nanoemulsion de aminosilicona.
EA201591995A1 (ru) Сконструированные полипептиды фенилаланин-аммиак-лиазы
EP3317294A4 (fr) Peptides stabilisés anti-microbiens
MX2016001094A (es) Nanoemulsion de aminosilicona.
BR112013028251A2 (pt) polipeptídeo
DK3328416T3 (da) Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
PT3058936T (pt) Composição peptídica e respetivos usos
DK3434760T3 (da) Fremgangsmåder til forøgelse af mannose-indholdet i rekombinante proteiner
ZA201508661B (en) Antifungal plant proteins, peptides, and methods of use
EP2970392A4 (fr) Peptides sos1 stabilisés
IL257986A (en) Expression of recombinant proteins in Trichoplusia ni pupa
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
EP3048110A4 (fr) Composition comprenant un peptide dérivé d'adiponectine
ZA201604055B (en) Stable compositions of peptide epoxy ketones
EP2968498A4 (fr) Préparations contenant un polypeptide du facteur ix
EP2971035A4 (fr) Production de polypeptide recombiné
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
IL245255B (en) Recombinant glycoproteins and their uses
PT3061771T (pt) Novo péptido unido a quatro epitopos ctl